Article
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.
Cancer immunology, immunotherapy : CII - 1 Jul 2023
Feils A S, Erbe A K, Birstler J, Kim K, Hoch U, Currie S L, Nguyen T, Yu D, Siefker-Radtke A O, Tannir N, Tolaney S M, Diab A, Sondel P M
Abstract excerpt
Bempegaldesleukin (BEMPEG), a CD122-preferential IL2 pathway agonist, has been shown to induce proliferation and activation of NK cells. NK activation is dependent on the balance of inhibitory and excitatory signals transmitted by NK receptors, including Fc-gamma receptors (FCγRs) and killer immunoglobulin-like receptors (KIRs) along with their KIR-ligands. The repertoire of KIRs/KIR-ligands an individual...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.